Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback